Clinical trials: Geriatric Cancer Patients
Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is among the most common hematologic malignancies in adults and accounts for approximately 10,000 deaths in the United States every year. AML is commonly diagnosed in sixth or seventh decades of life.
- Conditions
- Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
- Trial name
- NCT03226418
- Testing
- Cytarabine, Decitabine, Idarubicin
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Nebraska
Lung Cancer
Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00124618
- Testing
- cetuximab, radiation therapy
- Where
- 175 sites in United States
- Volunteers
- 58 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-Hodgkins Lymphoma
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
The purposes of this trial are to decrease toxicity and improve treatment effectiveness elderly patients. With a short course of chemotherapy with cyclophosphamide, mitoxantrone, vincristine, and prednisone with concurrent…
- Trial name
- NCT00193479
- Testing
- Cyclophosphamide, Mitoxantrone, Vincristine
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- SCRI Development Innovations, LLC
Lymphoma
Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, vincristine, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00690560
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Antoine Lacassagne
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00891878
- Testing
- capecitabine, sunitinib malate
- Where
- 182 sites in United States
- Volunteers
- 12 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL
This study is to evaluate the safety and clinical activity of idelalisib alone and in combination with rituximab in patients with CLL or SLL.
- Trial name
- NCT01203930
- Testing
- Idelalisib, Rituximab
- Where
- 6 sites in United States
- Volunteers
- 105 people
- Sponsor
- Gilead Sciences
Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
This clinical trial studies decitabine and cytarabine in treating older patients with newly diagnosed acute myeloid leukemia, myelodysplastic syndrome that is likely to come back or spread to other places in the body, or…
- Conditions
- Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Untreated Adult Acute Myeloid Leukemia
- Trial name
- NCT02121418
- Testing
- Cytarabine, Decitabine, Laboratory Biomarker Analysis
- Where
- 9 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of Washington
Astrocytoma, Grade III, Glioblastoma
Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.
This is a three parallel cohort, open-labeled, non-randomized, multicenter study. All three cohorts will enroll independently.
- Trial name
- STEAM (NCT03224104)
- Testing
- TG02, Radiation Therapy, Temozolomide
- Where
- 10 sites in Austria, France and 3 more
- Volunteers
- 71 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer
This phase II trial studies the side effects and how well vinorelbine tartrate and paclitaxel works in treating older patients with non-small cell lung cancer that has spread to other placed in the body.
- Trial name
- NCT00602797
- Testing
- Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Nebraska
Acute Myeloid Leukemia
Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML
This study is being done to determine if treatment with azacitidine and venetoclax is effective treatment for elderly patients with acute myeloid leukemia (AML) who have not received previous treatment.
- Trial name
- NCT03466294
- Testing
- Azacitidine and Venetoclax
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Colorado, Denver
Acute Myeloid Leukemia
GRASPA Treatment for Patients With Acute Myeloblastic Leukemia
The protocol aims at adding GRASPA (L-asparaginase encapsulated in red blood cells, eryaspase) to standard chemotherapy (low-dose cytarabine) to treat patients older than 65 years diagnosed with AML and unfit for intensive…
- Trial name
- ENFORCE (NCT01810705)
- Testing
- GRASPA
- Where
- 21 sites in France
- Volunteers
- 123 people
- Sponsor
- ERYtech Pharma
Cancer
Assessing Patient-reported & Patient-related Outcomes in Randomized Cancer Trials for Older Adults
As older adults with cancer are underrepresented in randomized clinical trials (RCT), there is limited evidence on which to rely for treatment decisions for this population.
- Trial name
- DATECANelderly (NCT03676218)
- Testing
- Elderly cancer patients
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Institut Bergonié
Cancer
Automated Geriatric Co-Management Program in Older Patients With Solid Mass or Nodule Suspicious for Cancer
The purpose of this study is to find out if it is possible to use the automated geriatric co-management program to manage the participants care before, during and after surgery.
- Trial name
- NCT03885908
- Testing
- in-person geriatric co-management, automated geriatric co-management
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastric Cancer
Evaluation of Efficacy and Safety of FOLFIRI Association Treatment in Patients 70 Years of Age and Older With Gastric Cancer
The number of patients over 70 years old with cancer is increasing in France. This population is heterogenous: physiological functions, presence of co-morbidities, and autonomy can vary a lot between subjects of the same age.
- Trial name
- CEPAFIRI (NCT00210184)
- Testing
- Irinotecan associated to fluorouracil and leucovorin
- Where
- 6 sites in France
- Volunteers
- 42 people
- Sponsor
- Institut Bergonié
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer
This 2 arm study will compare the efficacy and safety of sequential treatment with Tarceva and gemcitabine, and of gemcitabine monotherapy, as first line treatment of elderly patients, or patients with ECOG performance status of…
- Trial name
- NCT00940875
- Testing
- erlotinib [Tarceva], gemcitabine
- Where
- 17 sites in Australia
- Volunteers
- 54 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Colorectal Cancer
Expectations and Priorities of Elderly Patients for a First Medical Treatment for Cancer
The main objective of study is to describe the priorities of elderly patients (70 years and over) undergoing a first medical treatment for cancer, at initiation of treatment and after 3 months of treatment.
- Conditions
- Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer
- Trial name
- PRIORITY (NCT02821793)
- Testing
- Consultation, evaluation questionnaire, Geriatric consultation, evaluation questionnaire
- Where
- France
- Volunteers
- 346 people
- Sponsor
- Institut Bergonié
Esophageal Cancer
Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00524121
- Testing
- erlotinib hydrochloride, immunohistochemistry staining method, radiation therapy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Roswell Park Cancer Institute
Colorectal Cancer
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
This multicenter, prospective, observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in first-line therapy in elderly patients with metastatic colorectal cancer.
- Trial name
- NCT01555762
- Where
- 166 sites in France
- Volunteers
- 402 people
- Sponsor
- Hoffmann-La Roche
Hematologic Malignancy
Patient-Centered Care for the Older Adult With Hematologic Malignancy
This research study is evaluating if co-management by a geriatrician embedded in the oncology clinic can improve outcomes for frail older adults with blood cancers.
- Trial name
- NCT02359838
- Testing
- Baseline Geriatric Screening/Assessment, Geriatrician Co-Management
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Dana-Farber Cancer Institute
Stage III Non-small-cell Lung Cancer
Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC
Elderly (age 70 years or older) or >18 years old AND poor risk (ECOG 2) newly diagnosed stage IIIA-C (AJCC 8th edition) inoperable non-small cell lung cancer (NSCLC) patients are eligible to participate in this phase II open…
- Trial name
- ESR1814205 (NCT04441138)
- Testing
- Durvalumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Rush University Medical Center